BIBRIDGED Trademark

Trademark Overview


On Wednesday, August 31, 2022, a trademark application was filed for BIBRIDGED with the United States Patent and Trademark Office. The USPTO has given the BIBRIDGED trademark a serial number of 79352396. The federal status of this trademark filing is REGISTERED as of Tuesday, January 30, 2024. This trademark is owned by Biosynth B.V.. The BIBRIDGED trademark is filed in the Pharmaceutical Products category with the following description:

Synthetic peptides for pharmaceutical purposes, namely for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; Peptides for pharmaceutical purposes, namely for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptides for medical diagnostical purposes; peptides for diagnostical purposes in medical fields; peptides for serological purposes for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptides for radioimaging purposes in medical fields, namely diagnostic kits consisting primarily of monoclonal antibodies or mimics thereof consisting of peptides, buffers, and reagents for use in disease testing; peptides for use in the field of oncology for the treatment of cancer; pharmaceutical preparations based on peptides for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptide mimics of antibodies for medical purposes
bibridged

General Information


Serial Number79352396
Word MarkBIBRIDGED
Filing DateWednesday, August 31, 2022
Status700 - REGISTERED
Status DateTuesday, January 30, 2024
Registration Number7292366
Registration DateTuesday, January 30, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 14, 2023

Trademark Statements


Goods and ServicesSynthetic peptides for pharmaceutical purposes, namely for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; Peptides for pharmaceutical purposes, namely for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptides for medical diagnostical purposes; peptides for diagnostical purposes in medical fields; peptides for serological purposes for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptides for radioimaging purposes in medical fields, namely diagnostic kits consisting primarily of monoclonal antibodies or mimics thereof consisting of peptides, buffers, and reagents for use in disease testing; peptides for use in the field of oncology for the treatment of cancer; pharmaceutical preparations based on peptides for the treatment of cancer, inflammatory diseases, skin disorders, eye disorders; peptide mimics of antibodies for medical purposes

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 14, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBiosynth B.V.
Party Type30 - Original Registrant
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Party NameBiosynth B.V.
Party Type20 - Owner at Publication
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Party NameBiosynth B.V.
Party Type10 - Original Applicant
Legal Entity Type26 - NOT AVAILABLE
AddressNL

Trademark Events


Event DateEvent Description
Thursday, October 13, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, October 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 18, 2022APPLICATION FILING RECEIPT MAILED
Friday, November 25, 2022CHANGE OF NAME/ADDRESS REC'D FROM IB
Friday, June 16, 2023ASSIGNED TO EXAMINER
Wednesday, June 21, 2023NON-FINAL ACTION WRITTEN
Thursday, June 22, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, July 27, 2023REFUSAL PROCESSED BY MPU
Thursday, July 27, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Tuesday, August 15, 2023REFUSAL PROCESSED BY IB
Friday, September 22, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 22, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, September 23, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 25, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, October 25, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, October 25, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, November 14, 2023PUBLISHED FOR OPPOSITION
Tuesday, November 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, November 17, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, November 17, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, November 17, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, December 2, 2023NEW REPRESENTATIVE AT IB RECEIVED
Monday, November 13, 2023NOTIFICATION PROCESSED BY IB
Friday, November 17, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, November 17, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, January 30, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, January 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 30, 2024FINAL DISPOSITION PROCESSED
Tuesday, April 30, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Wednesday, May 1, 2024FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, May 21, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Saturday, December 9, 2023NEW REPRESENTATIVE AT IB RECEIVED